Sonoma Biotherapeutics
Becky brings over 25 years of experience in the biotech industry to Sonoma. She has worked in various focus areas including autoimmunity and oncology and has extensive experience in the development of complex primary immune cell-based functional assays in both the immune-oncology and autoimmune settings. This work has included target validation using CRISPR mediated gene editing, small molecules, and biologics.
Becky received a B.A. in biology from St. Olaf College and an M.S. in biology from the University of Michigan. Prior to Sonoma, she worked at ZymoGenetics, Novo Nordisk, and Celgene, all in Seattle.
Becky is a member of Sonoma’s Translational Development team.
This person is not in any offices
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.